A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered in Combination With Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-001) [EXTENSION OF 700039214]
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Certolizumab pegol (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 30 Oct 2013 Post-hoc analysis assessing rates of comprehensive disease control and comprehensive disease remission presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Mar 2013 New trial record